During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

The study reviews CAR-T cell advancements in lymphoma treatment, addressing T cell exhaustion and tumor immune evasion with ...

Tumor cells often secrete lncRNAs into the surrounding stroma, where they can bind to receptors on stromal cells and alter their behavior, thus reinforcing tumor cell growth and survival.

T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.

That led them to develop new receptors, now called SNIPRs (synthetic intramembrane proteolysis receptors), which can bind to soluble, or free-floating, molecules in the environment around a cell.

The breakthrough, appearing in Nature on Nov. 14, revolves around engineered receptors on the surface of cells that can sense molecules in the surrounding environment and, in response, change the ...

Host mice deficient in IFNγ receptors showed uncontrolled leptomeningeal tumor growth, yet subcutaneous or orthotopic tumors remained unchanged. T cells emerged as the primary source of IFNγ ...

Every cell has a story: Tumor and immune cell interactions within craniopharyngiomas. ScienceDaily . Retrieved June 11, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241216125920.htm ...

The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma. It’s the first engineered cell therapy approved for treating a solid tumor.

The stages of squamous cell carcinoma range from 0–4. Stage 0 is a precancerous stage, and stage 4 is advanced or metastatic cancer.